News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
429,006 Results
Type
Article (33424)
Company Profile (162)
Press Release (395412)
Multimedia
Podcasts (81)
Webinars (10)
Section
Business (120188)
Career Advice (1095)
Deals (22104)
Drug Delivery (83)
Drug Development (50950)
Employer Resources (95)
FDA (10685)
Job Trends (9440)
News (205670)
Policy (19169)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1857)
Academic (1)
Accelerated approval (24)
Adcomms (16)
Allergies (80)
Alliances (31011)
ALS (132)
Alzheimer's disease (1133)
Antibody-drug conjugate (ADC) (247)
Approvals (10870)
Artificial intelligence (482)
Autoimmune disease (114)
Automation (30)
Bankruptcy (174)
Best Places to Work (7871)
BIOSECURE Act (15)
Biosimilars (130)
Biotechnology (130)
Bladder cancer (121)
Brain cancer (47)
Breast cancer (447)
Cancer (3690)
Cardiovascular disease (295)
Career advice (932)
Career pathing (18)
CAR-T (229)
CDC (20)
Celiac Disease (1)
Cell therapy (647)
Cervical cancer (27)
Clinical research (43515)
Collaboration (1401)
Company closure (1)
Compensation (446)
Complete response letters (43)
COVID-19 (1800)
CRISPR (99)
C-suite (589)
Cystic fibrosis (133)
Data (4811)
Denatured (15)
Depression (105)
Diabetes (345)
Diagnostics (4963)
Digital health (27)
Diversity (5)
Diversity, equity & inclusion (32)
Drug discovery (238)
Drug pricing (109)
Drug shortages (13)
Duchenne muscular dystrophy (227)
Earnings (54334)
Editorial (43)
Employer branding (14)
Employer resources (88)
Events (56916)
Executive appointments (619)
FDA (13041)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (10)
Frontotemporal dementia (18)
Funding (1101)
Gene editing (217)
Generative AI (51)
Gene therapy (671)
GLP-1 (644)
Government (2600)
Grass and pollen (4)
Guidances (358)
Healthcare (11857)
HIV (44)
Huntington's disease (45)
IgA nephropathy (65)
Immunology and inflammation (161)
Immuno-oncology (44)
Indications (67)
Infectious disease (1982)
Inflammatory bowel disease (138)
Inflation Reduction Act (9)
Influenza (79)
Intellectual property (183)
Interviews (189)
IPO (11058)
IRA (22)
Job creations (1941)
Job search strategy (775)
JPM (46)
Kidney cancer (13)
Labor market (42)
Layoffs (396)
Leadership (20)
Legal (4587)
Liver cancer (62)
Longevity (11)
Lung cancer (511)
Lymphoma (312)
Machine learning (38)
Management (26)
Manufacturing (593)
MASH (111)
Medical device (7351)
Medtech (7378)
Mergers & acquisitions (11881)
Metabolic disorders (866)
Multiple sclerosis (109)
NASH (12)
Neurodegenerative disease (247)
Neuropsychiatric disorders (66)
Neuroscience (2081)
Neurotech (1)
NextGen: Class of 2026 (3674)
Non-profit (2744)
Now hiring (24)
Obesity (400)
Opinion (226)
Ovarian cancer (119)
Pain (126)
Pancreatic cancer (151)
Parkinson's disease (201)
Partnered (24)
Patents (348)
Patient recruitment (341)
Peanut (27)
People (33629)
Pharmaceutical (25)
Pharmacy benefit managers (19)
Phase 1 (14385)
Phase 2 (19098)
Phase 3 (14360)
Pipeline (4265)
Policy (167)
Postmarket research (1425)
Preclinical (6148)
Press Release (70)
Prostate cancer (172)
Psychedelics (29)
Radiopharmaceuticals (216)
Rare diseases (788)
Real estate (2825)
Recruiting (35)
Regulatory (15163)
Reports (32)
Research institute (1797)
Resumes & cover letters (183)
Rett syndrome (28)
RNA editing (17)
RSV (48)
Schizophrenia (125)
Series A (202)
Series B (143)
Service/supplier (5)
Sickle cell disease (101)
Special edition (14)
Spinal muscular atrophy (165)
Sponsored (35)
Startups (2326)
State (1)
Stomach cancer (10)
Supply chain (66)
Tariffs (44)
The Weekly (65)
Vaccines (683)
Venture capital (62)
Weight loss (252)
Women's health (46)
Worklife (8)
Date
Today (46)
Last 7 days (407)
Last 30 days (1436)
Last 365 days (22042)
2026 (2081)
2025 (22313)
2024 (24756)
2023 (27465)
2022 (35969)
2021 (38137)
2020 (34885)
2019 (27892)
2018 (21367)
2017 (20504)
2016 (18780)
2015 (21822)
2014 (15633)
2013 (20880)
2012 (13166)
2011 (13678)
2010 (12481)
Location
Africa (507)
Alabama (35)
Alaska (3)
Arizona (142)
Arkansas (5)
Asia (25948)
Australia (4558)
California (7768)
Canada (2377)
China (819)
Colorado (306)
Connecticut (312)
Delaware (226)
Europe (61795)
Florida (1135)
Georgia (215)
Hawaii (3)
Idaho (37)
Illinois (534)
India (54)
Indiana (350)
Iowa (18)
Japan (325)
Kansas (89)
Kentucky (34)
Louisiana (20)
Maine (49)
Maryland (952)
Massachusetts (5841)
Michigan (239)
Minnesota (285)
Mississippi (5)
Missouri (95)
Montana (16)
Nebraska (12)
Nevada (86)
New Hampshire (48)
New Jersey (2258)
New Mexico (18)
New York (2063)
North Carolina (960)
North Dakota (9)
Northern California (3873)
Ohio (227)
Oklahoma (3)
Oregon (18)
Pennsylvania (1512)
Puerto Rico (15)
Rhode Island (28)
South America (660)
South Carolina (30)
South Dakota (1)
Southern California (2952)
Tennessee (89)
Texas (1215)
United States (27453)
Utah (255)
Vermont (1)
Virginia (170)
Washington D.C. (51)
Washington State (663)
West Virginia (4)
Wisconsin (79)
Wyoming (2)
429,006 Results for "gene by gene".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene editing
Lilly Leans Into Hearing Loss in $1.12B+ Gene Editing Pact With Seamless
The deal will help bolster Eli Lilly’s growing hearing loss portfolio, which is anchored by the gene therapy AK-OTOF.
January 28, 2026
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.
January 26, 2026
·
2 min read
·
Dan Samorodnitsky
Rare diseases
FDA Greenlights First Gene Therapy for Rare Pediatric Disease
Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a non-profit sponsor to win FDA approval.
December 10, 2025
·
1 min read
·
Tristan Manalac
Opinion
Cell and Gene Therapy Will Transform Lives—If We Let It
Mixed headlines have plagued the cell and gene therapy space of late. We believe that a renewed case of optimism is not only warranted but essential if these therapies are to reach their full potential.
November 24, 2025
·
8 min read
·
Tim Hunt
Gene editing
FDA Eyes Accelerated Reviews for Gene Editing Therapies
Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to outline his office’s thinking on accelerating gene editing reviews.
November 3, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Imposes Boxed Warning, Narrows Patient Pool for Sarepta’s Duchenne Gene Therapy Elevidys
Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed with the gene therapy.
November 17, 2025
·
1 min read
·
Tristan Manalac
Approvals
Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight
The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access to patients two years and older in what one Stanford Medicine professor called a “game changing advance” for the field.
November 25, 2025
·
3 min read
·
Heather McKenzie
Earnings
BioMarin Abandons Gene Therapy Roctavian, Cuts Revenue Guidance as Voxzogo Faces Competitors
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending competition for achondroplasia therapy Voxzogo and the divestment of the gene therapy Roctavian.
October 28, 2025
·
4 min read
·
Tristan Manalac
Gene therapy
AviadoBio Looks to China for Eye-Based Gene Therapy in $413M UgeneX Pact
AviadoBio will have the option to exclusively license UGX-202, a vision-restoring gene therapy for the rare eye condition retinitis pigmentosa.
October 10, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA Details Thinking for Streamlining Development of Cell, Gene, Regenerative Therapies
Three draft recommendation documents published on Wednesday are intended to guide drug sponsors and accelerate the development of cell and gene therapies.
September 25, 2025
·
2 min read
·
Tristan Manalac
1 of 42,901
Next
